Low Ankle-Brachial Index Relates to Alzheimer-Signature Cerebral Glucose Metabolism in Cognitively Impaired Older Adults

Seok Woo Moon\textsuperscript{a}, Min Soo Byun\textsuperscript{b,c}, Dahyun Yi\textsuperscript{d}, Min Jung Kim\textsuperscript{e}, Joon Hyung Jung\textsuperscript{b}, Nayeong Kong\textsuperscript{b}, Gijung Jung\textsuperscript{d}, Hyejin Ahn\textsuperscript{d}, Jun-Young Lee\textsuperscript{f}, Koung Mi Kang\textsuperscript{g}, Chul-Ho Sohn\textsuperscript{h}, Yu Kyeong Kim\textsuperscript{h}, Dong Young Lee\textsuperscript{b,c,d,*} and for the KBASE Research Group\textsuperscript{i}

\textsuperscript{a}Department of Neuropsychiatry & Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, Republic of Korea

\textsuperscript{b}Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea

\textsuperscript{c}Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea

\textsuperscript{d}Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul, Republic of Korea

\textsuperscript{e}Department of Psychiatry, Eulji University Nowon Eulji Medical Center, Seoul, Republic of Korea

\textsuperscript{f}Department of Neuropsychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea

\textsuperscript{g}Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea

\textsuperscript{h}Department of Nuclear Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea

Accepted 16 February 2023
Pre-press 13 March 2023

Abstract.

\textbf{Background:} Ankle-brachial index (ABI), an indicator of atherosclerosis or arterial stiffness, has been associated with Alzheimer's disease (AD) dementia and related cognitive impairment. Nevertheless, only limited information is available regarding its contribution to brain alterations leading to cognitive decline in late-life.

\textbf{Objective:} We aimed to investigate the relationship of ABI with in vivo AD pathologies and cerebrovascular injury in cognitively impaired older adults.

\textbf{Methods:} Total 127 cognitively impaired (70 mild cognitive impairment and 57 AD dementia) individuals, who participated in an ongoing prospective cohort study, were included. All participants underwent comprehensive clinical and neuropsychological assessment, ABI measurement, apolipoprotein E (\textit{APOE} \textit{ε}4 genotyping, and multi-modal brain imaging including \textsuperscript{[11C]} Pittsburgh Compound B (PiB)-positrone emission tomography (PET) and \textsuperscript{[18F]} fludeoxyglucose (FDG)-PET, and MRI.

\textbf{Results:} General linear model analysis showed significant relationship between ABI strata (low ABI: <1.00, normal ABI: \textasciitilde1.30, and high ABI: \textasciitilde1.30) and AD-signature region cerebral glucose metabolism (AD-CM), even after controlling

\textsuperscript{i}The coinvestigators of the KBASE Research Group are listed elsewhere (https://kbase.kr).

\textsuperscript{*}Correspondence to: Dong Young Lee, MD, PhD, Department of Neuropsychiatry, Seoul National University Hospital & Department of Psychiatry, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Tel.: +82 2 2072 2205; Fax: +82 2 744 7241; E-mail: selfpsy@snu.ac.kr.
age, sex, clinical dementia rating–sum of box, and APOE ε4 positivity \( (p = 0.029) \). Post hoc comparison revealed that low ABI had significantly lower AD-CM than middle and high ABI, while no difference of AD-CM was found between middle and high ABI. There was no significant difference of global Aβ deposition, AD-signature region cortical thickness, and white matter hyperintensity volume between the three ABI strata.

**Conclusion:** Our findings suggest that lower ABI, likely related to atherosclerosis, may contribute to the aggravation of AD-related regional neurodegeneration in cognitively impaired older adults.

Keywords: Alzheimer's disease, ankle-brachial index, cerebral Aβ deposition, mild cognitive impairment, neurodegeneration

---

**INTRODUCTION**

The ankle-brachial pressure index (ABI), the ratio of the ankle and brachial systolic blood pressure (SBP), is a widely used non-invasive measure of arterial health. A low ABI reflects the presence of atherosclerosis of the arterial walls in the lower extremities and it is regarded as a good indicator of generalized atherosclerosis [1, 2], while high ABI indicates arterial stiffness or arteriosclerosis of the vessel wall [3, 4].

Several epidemiological studies showed that low ABI was related to an increased risk or progression of AD and related cognitive impairment, suggesting the presence of relationship of atherosclerosis of cerebral arteries to AD dementia and cognitive decline in older adults [2, 5–7]. Some studies also reported that both high and low ABI were related to increased risk of cognitive impairment or dementia, particularly a U-shaped relationship [8, 9].

Nevertheless, relatively limited information is available for brain alterations related to the relationship between ABI levels and cognitive impairment. While our group previously reported a positive association between a high ABI and increased amyloid-β (Aβ) burden in cognitively healthy older adults [10], to our knowledge, no studies examined the association between ABI levels and brain alterations such as AD pathologies and cerebrovascular injury in cognitively impaired individuals.

We aimed to investigate the relationship of ABI levels with in vivo AD pathologies and cerebrovascular injury measured by multi-modal brain imaging scans in older adults with cognitive impairment (CI).

**METHODS**

**Participants**

The present study was part of the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s Disease (KBASE) [11], an ongoing prospective cohort study, which started in 2014. In total, 127 older adults (55–90 years of age) with CI (i.e., 70 mild cognitive impairment (MCI) and 57 AD dementia patients) were included in this study. All individuals with MCI had a Clinical Dementia Rating (CDR) score of 0.5 and met the core clinical criteria for diagnosis of MCI according to the recommendations of the NIA-AA guidelines [12]. For the AD dementia group, participants who fulfilled the following inclusion criteria were recruited: 1) criteria for dementia in accordance with the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV-TR) [13], 2) the criteria for probable AD dementia in accordance with the NIA-AA guidelines [14], and 3) a global CDR score of 0.5 or 1. For both MCI and AD dementia groups, individuals with the following conditions were excluded from the study: 1) presence of major psychiatric illness; 2) significant neurological (e.g., cerebrovascular disease) or medical condition or comorbidities that could affect mental function; 3) contraindications to MRI (e.g., pacemaker, claustrophobia); 4) illiteracy; 5) presence of significant visual/hearing difficulty, and severe communication or behavioral problems that would make clinical examination or brain scan difficult; 6) taking an investigational drug; and 7) pregnant or breastfeeding. Details of the KBASE cohort and recruitment of participants were previously described [11]. The study protocol was approved by the Institutional Review Boards of Seoul National University Hospital (C-1401-027-547) and SNU-SMG Boramae Center (26–2015-60), Seoul, South Korea, and was conducted in accordance with the recommendations of the current version of the Declaration of Helsinki. All participants or their legal representatives provided written informed consent to participate in this study after receiving a complete description of the study.

**Clinical and neuropsychological assessments**

All subjects underwent standardized clinical assessments by trained psychiatrists based on the
KBASE clinical assessment protocol which incorporated the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K) [15]. The KBASE neuropsychological assessment protocol incorporating the CERAD-K neuropsychological battery [16] was also administered to all participants by trained neuropsychologist or psychometrists. Reliable informants provided information regarding participants’ cognitive, emotional, and functional changes as well as medical history. A panel of psychiatrists and a clinical neuropsychologist with expertise in dementia research made clinical decisions regarding the CI (i.e., MCI or AD dementia) diagnosis and CDR.

Determining the APOE genotype

Genomic DNA was extracted from venous blood, and apolipoprotein E (APOE) genotyping was performed according to the method described by Wenham et al. [17].

Measurement of ABI

At baseline, SBP in the right arm (brachial artery) and the bilateral ankle (posterior tibial artery) was measured three times in the supine position using a hand-held Doppler device (BIDOP ES-100V3, Hadeco, Inc., Kawasaki, Japan) following the standard protocol [2, 18, 19]. The mean of the three measurements for each ankle and for the right arm was calculated for each individual. ABI was computed by dividing the average of each ankle SBP by the average of the brachial SBP measurements, and the lower ABI value was chosen [2, 18, 19].

Measurement of cerebral Aβ deposition

Participants underwent simultaneous three-dimensional (3D) PiB-PET and 3D T1-weighted MRI using a 3.0T Biograph mMR (PET-MR) scanner (Siemens, Washington DC, USA) according to the manufacturer's guidelines. Details of PiB-PET image acquisition and preprocessing are presented in the Supplementary Methods. AD-signature FDG ROIs including the angular gyri, posterior cingulate cortex, and inferior temporal gyri, which are sensitive to alterations associated with AD [23], were determined. AD-signature region cerebral glucose metabolism (AD-CM) was defined as voxel-weighted mean SUVR extracted from the AD-signature FDG ROIs. Details of MR image acquisition and preprocessing are also presented in the Supplementary Methods. AD-signature region cortical thickness (AD-CT) was defined as a mean cortical thickness values obtained from AD-signature regions, including the entorhinal, inferior temporal, middle temporal, and fusiform gyrus, according to a previous study [24].

Measurement of white matter hyperintensities

Participants underwent MRI scans with fluid attenuated inversion recovery (FLAIR) using the same 3.0T PET-MR scanner. We used a previously validated automatic procedure [25] in order to measure white matter hyperintensity (WMH) volume. Details of the volume measurement of WMH are presented in the Supplementary Methods.

Statistical analysis

Referring to previous reports which indicated a U-shape relationship between ABI and cognitive impairment (i.e., the contribution of both low and high ABI to cognitive decline) [8, 9], we divided the ABI into three strata, i.e., low ABI: <1.00, normal values for each ROI were calculated by dividing the mean value for all voxels within each ROI by the mean cerebellar uptake value in the same image. A global cortical ROI consisting of the four ROIs was also defined, and a global Aβ retention value was generated by dividing the mean value for all voxels of the global cortical ROI by the mean cerebellar uptake value in the same image [20, 21]. Each participant was classified as Aβ positive (Aβ+) if the global Aβ retention value was >1.21 or as Aβ negative (Aβ−) if the global Aβ retention value was ≤1.21 [22].
ABI: 1.00–1.29, and high ABI: ≥1.30, to identify the ABI level that primarily affects neuroimaging markers. This categorization was based on reports suggesting that an ABI <1.00 may indicate subclinical atherosclerosis in lower extremity arteries [2], and that an ABI value of 1.30 is the cut-off point at which the ABI reflects arterial stiffness [26]. Group differences of participant characteristics between the low ABI, normal ABI, and high ABI groups were analyzed by analysis of variance or chi-squared test. The differences in imaging markers were tested among ABI strata using the general linear model (GLM) analysis with post-hoc tests using the least significant difference (LSD) method (pairwise comparison). The model included age, gender, APOE ε4 positivity, and CDR-SOB as covariates. To explore the moderating effects of age [younger (≤70 years) versus older (>70 years)], sex, and APOE ε4 positivity on the association between ABI and the neuroimaging biomarker(s), additional GLM analyses were conducted including a two-way interaction term between the ABI strata and each of the factors mentioned above as an additional independent variable. All statistical analyses were conducted using SPSS software (ver. 20.0 for Windows; SPSS Inc., Chicago, IL, USA) and a two-tailed p-value <0.05 was considered significant.

RESULTS

Demographic and clinical characteristics of the subjects

The demographic and clinical characteristics of the subjects are presented in Table 1. There were significant differences for sex, blood pressure, AD-CM, and AD-CT between the low, normal, and high ABI groups. However, age, APOE ε4 positivity, CDR (0.5/1), CDR-SOB, MMSE score, global Aβ retention value, or WMH volume did not show significant differences between the three ABI groups.

Association between the ABI and cerebral Aβ deposition

As shown in Table 2, GLM analysis controlling age, gender, APOE ε4 status, and CDR-SOB as covariates showed that the three stratified ABI groups did not have significantly different global Aβ retention.

Association between the ABI and AD-signature region neurodegeneration

In contrast to the finding for Aβ retention, there were significantly different AD-CM values between the three ABI groups even after controlling age, sex, APOE ε4 positivity, and CDR-SOB as covariates (Table 2). The post-hoc comparisons showed that low ABI group had significantly lower AD-CM than both normal and high ABI groups (Fig. 1). In regard of AD-CT, however, we did not find any significant difference between the ABI groups after controlling the same covariates (Table 2).

Association between the ABI and white matter hyperintensities

There was no significant association of the ABI groups with WMH volume after controlling for age, sex, CDR-SOB, and APOE ε4 positivity (Table 2).

Moderation of age, sex, and APOE ε4 positivity on the association between ABI and neuroimaging biomarkers

Exploratory analyses demonstrated that there was no significant ABI groups × age (or ABI group × sex or ABI group × APOE ε4 positivity) interaction effect on any neuroimaging biomarkers (Table 3).

DISCUSSION

In the present study, we found that low ABI group had significantly lower AD-CM than the other ABI groups after controlling for the effects of CDR-SOB, a measure of functional severity by cognitive impairment, as well as age, sex, and APOE ε4 positivity. The finding is comparable with the previous reports that a low ABI was related to an increased risk of cognitive impairment or dementia syndrome including AD dementia [2, 5, 7, 27]. This probably corresponds to the left side of the U-shaped relationship found previously between the ABI and cognitive impairment [8]. Given that a lower ABI is an indicator of generalized atherosclerosis [1, 2] including atherosclerosis in the brain [28, 29], cerebral atherosclerosis may causes a lowered cerebral perfusion, which can induce subsequent brain hypometabolism through reduced oxygen supply [5, 28].

In contrast to AD-CM, neither AD-CT nor WMH volume was related to low ABI. This may be explained by the fact that we excluded subjects with
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (n = 127)</th>
<th>Low ABI (n = 14)</th>
<th>Normal ABI (n = 87)</th>
<th>High ABI (n = 26)</th>
<th>F/χ²</th>
<th>p for low versus normal ABI</th>
<th>p for low versus high ABI</th>
<th>p for normal versus high ABI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>73.17 (7.30)</td>
<td>75.35 (6.76)</td>
<td>72.92 (7.18)</td>
<td>72.81 (8.04)</td>
<td>0.708</td>
<td>0.495</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender (male)</td>
<td>38 (29.9%)</td>
<td>8 (57.1%)</td>
<td>17 (21.8%)</td>
<td>13 (50.0%)</td>
<td>14.420 (χ²)</td>
<td>0.001*</td>
<td>&lt;0.05</td>
<td>NS</td>
</tr>
<tr>
<td>Education (y)</td>
<td>9.82 (5.20)</td>
<td>10.57 (5.47)</td>
<td>9.37 (5.14)</td>
<td>10.92 (5.25)</td>
<td>1.061</td>
<td>0.349</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE ε4 (+)</td>
<td>59 (46.4%)</td>
<td>5 (35.7%)</td>
<td>40 (45.9%)</td>
<td>14 (53.8%)</td>
<td>1.228 (χ²)</td>
<td>0.541</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>123.54 (17.84)</td>
<td>120.71 (21.65)</td>
<td>127.24 (16.96)</td>
<td>112.69 (14.02)</td>
<td>7.569</td>
<td>0.001*</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>77.09 (10.77)</td>
<td>72.85 (13.36)</td>
<td>78.97 (1.035)</td>
<td>73.08 (9.28)</td>
<td>4.432</td>
<td>0.014*</td>
<td>0.045</td>
<td>0.029</td>
</tr>
<tr>
<td>CDR (0.5/1)</td>
<td>89/38</td>
<td>9/5</td>
<td>63/24</td>
<td>17/9</td>
<td>0.724 (χ²)</td>
<td>0.696</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR (SOB)</td>
<td>3.12 (1.91)</td>
<td>3.50 (2.17)</td>
<td>2.90 (1.81)</td>
<td>3.68 (2.04)</td>
<td>1.986</td>
<td>0.142</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMSE</td>
<td>19.65 (4.44)</td>
<td>18.07 (4.20)</td>
<td>20.08 (4.62)</td>
<td>19.04 (3.80)</td>
<td>1.553</td>
<td>0.216</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis (MCI/AD)</td>
<td>70/57</td>
<td>7/7</td>
<td>52/35</td>
<td>11/15</td>
<td>2.634 (χ²)</td>
<td>0.268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global Aβ retention value</td>
<td>1.76 (0.50)</td>
<td>1.69 (0.46)</td>
<td>1.74 (0.50)</td>
<td>1.86 (0.554)</td>
<td>0.688</td>
<td>0.505</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD-CM</td>
<td>1.36 (0.15)</td>
<td>1.25 (0.08)</td>
<td>1.36 (0.15)</td>
<td>1.36 (0.15)</td>
<td>3.792</td>
<td>0.025*</td>
<td>0.007</td>
<td>0.025</td>
</tr>
<tr>
<td>AD-CT</td>
<td>2.52 (0.29)</td>
<td>2.37 (0.31)</td>
<td>2.56 (0.29)</td>
<td>2.47 (0.25)</td>
<td>3.053</td>
<td>0.051</td>
<td>0.026</td>
<td>NS</td>
</tr>
<tr>
<td>WMH</td>
<td>6.01 (5.18)</td>
<td>6.16 (4.20)</td>
<td>6.09 (5.35)</td>
<td>6.60 (5.31)</td>
<td>0.076</td>
<td>0.926</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ABI, ankle brachial index; APOE, apolipoprotein E; Aβ, cerebral amyloid-β; BP, blood pressure; CDR, Clinical Dementia Rating; SOB, sum of boxes; MMSE, Mini-Mental State Examination; MCI, mild cognitive impairment; AD-CM, Alzheimer’s disease signature regional cerebral glucose metabolism; WMH, white matter hyperintensity; NS, non specific.
Table 2

Effect of the ABI on global cerebral $\beta\alpha$ retention, AD-CM, AD-CT, and WMH: Results from GLM analyses

<table>
<thead>
<tr>
<th>Neuroimaging markers</th>
<th>ABI strata (ABI $&lt;1.00$, 1.00 $\sim$ 1.29 and $\geq$ 1.30)</th>
<th>Type III SS</th>
<th>df</th>
<th>Mean square</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global A$\beta$ retention value</td>
<td>0.108</td>
<td>1</td>
<td>0.054</td>
<td>0.259</td>
<td>0.772</td>
<td></td>
</tr>
<tr>
<td>AD-CM</td>
<td>0.146</td>
<td>1</td>
<td>0.073</td>
<td>3.634</td>
<td>0.029</td>
<td></td>
</tr>
<tr>
<td>AD-CT</td>
<td>0.055</td>
<td>1</td>
<td>0.027</td>
<td>0.496</td>
<td>0.610</td>
<td></td>
</tr>
<tr>
<td>WMH</td>
<td>9.476</td>
<td>1</td>
<td>4.738</td>
<td>0.198</td>
<td>0.820</td>
<td></td>
</tr>
</tbody>
</table>

ABI, ankle brachial index; A$\beta$, cerebral amyloid- $\beta$; AD-CM, AD-signature region cerebral glucose metabolism; AD-CT AD-signature cortical thickness; WMH, white matter hyperintensity; SS, square sum. *p $<$ 0.05, p values by general linear model (GLM) analysis controlling age, gender, APOE $\varepsilon$4 positivity, and CDR-SOB as covariates.

A history of stroke or severe vascular lesions including infarcts and hemorrhages on brain MRI from the current study. Such strict application of exclusion criteria might result in ruling out subjects with severe cerebral atherosclerosis. In line with this, the number of subjects with a low ABI was relatively small ($n = 11$, 11.0%). Subsequently, it would be hard to detect the structural brain changes such as decrease of AD-CT and increase of WMH volume due to severe atherosclerosis.

There was no significant association between ABI and brain amyloid deposition. Such lack of significant finding for CI individuals in the present study appears contrast to our previous report for the association between high ABI and increased cerebral amyloid deposition in cognitively normal (CN) old adults [10]. This discrepancy may be due to the different range of cerebral amyloid accumulation levels between CN and CI individuals. Cerebral A$\beta$ deposition begins 10–20 years before development of AD dementia [30]. It gradually increases in the stage of CN and reaches a state of near saturation in the stages of MCI and dementia, i.e., CI stage [31, 32]. Therefore, detection of an association between ABI and cerebral A$\beta$ deposition may be difficult in CI compared to CN.

To the best of our knowledge, this study is the first to show association between low ABI and decreased AD-CM in CI individuals. Nevertheless, several limitations needed to be mentioned. First, as this was a cross-sectional study, causal relationship cannot be inferred. Further longitudinal studies are needed. Second, the relatively small number of subjects with abnormal ABI, low ABI subjects in particular, was included. This may have made it difficult to detect a weak association between ABI and brain biomarker. Third, there was a significant gender difference between normal ABI and low/high ABI groups in our participants. The difference could potentially affect the results. However, we statistically controlled gender as a covariates when analyzing between-ABI group difference of neuroimaging markers to minimize such potential confounding effect of it. In addition, we did not find any moderation effect of gender on the relationship between ABI group and neuroimaging markers as shown in Table 3. Given together, it is not likely that our findings were affected by between-group gender difference. Finally, only Asians (specifically Koreans) were included in this study. The prevalence of abnormal ABI status or peripheral arterial disease is lower in Asian or white older adults than black ones [33]. Given such ethnic difference for ABI and related arterial conditions, our observations need to be replicated further in other ethnic populations.
Table 3

Interaction effect of the ABI strata and APOE e4 positivity (or age, or gender) on neuroimaging biomarkers

<table>
<thead>
<tr>
<th></th>
<th>Global Aβ retention</th>
<th>AD-CM</th>
<th>AD-CT</th>
<th>WMH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Type III SS df Mean Square</td>
<td>F</td>
<td>p</td>
<td>Type III SS df Mean Square</td>
</tr>
<tr>
<td>APOE e4</td>
<td>1.959 1  1.959 9.239 0.005</td>
<td>0.255 0.615 0.060 1  1.064 0.305 44.533 1  1.835 0.178</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI = 1.00−1.29</td>
<td>0.013 2  0.006 0.030 0.010 2  0.034 0.263 0.076 0.200 2  0.010 0.176 0.839 7.566 2  0.156 0.856</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI ≥ 1.30</td>
<td>0.131 2  0.066 0.310 0.005</td>
<td>0.124 0.884 0.032 2  0.016 0.283 0.754 7.265 2  0.150 0.861</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE e4</td>
<td>3.667 1  3.667 17.589 &lt;0.001 0.004</td>
<td>1.207 0.274 0.091 1  0.091 1.618 0.206 71.732 1  1.732 0.295 0.089</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI = 1.00−1.29</td>
<td>0.537 2  0.269 1.289 0.011 2  0.006 0.276 0.759 0.039 2  0.020 0.349 0.706 4.173 2  0.086 0.918</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI ≥ 1.30</td>
<td>0.545 2  0.273 1.307 0.018 2  0.009 0.455 0.635 0.039 2  0.020 0.352 0.704 3.283 2  1.641 0.068 0.935</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE e4</td>
<td>3.564 1  3.564 16.946 &lt;0.001 0.022</td>
<td>1.062 0.305 0.097 1  0.097 1.750 0.189 80.717 1  8.071 3.473 0.065</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI = 1.00−1.29</td>
<td>0.379 2  0.189 0.901 0.009</td>
<td>0.861 0.426 0.156 2  0.078 1.411 0.248 18.670 2  9.335 0.402 0.670</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABI ≥ 1.30</td>
<td>0.329 2  0.165 0.783 0.016</td>
<td>0.401 0.670 0.108 2  0.054 0.971 0.382 112.663 2  56.332 2.424 0.094</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ABI, ankle brachial index; Aβ, cerebral amyloid-β; AD-CM, AD-signature region cerebral glucose metabolism; AD-CT, AD-signature cortical thickness; WMH, white matter hyperintensity; APOE, apolipoprotein E; SS, square sum; ABI strata, ABI <1.00, 1.00~1.29 and ≥1.30; CDR, Clinical Dementia Rating; SOB, sum of boxes. *p < 0.05, p values by general linear model (GLM) analysis controlling age, gender, APOE e4 positivity, and CDR-SOB as covariates.

In conclusion, the present findings suggest that lower ABI, probably related to cerebral atherosclerosis, may contribute to hypometabolism of AD-related brain regions in cognitively impaired older individuals.

Acknowledgments

We thank all the members of the KBASE Research Group for their contribution. Members of the KBASE Research Group are listed elsewhere (http://kbase.kr). We also sincerely thank the subjects for their participation in this study.

Funding

This study was supported by a grant from the Ministry of Science and ICT, Republic of Korea (grant No. NRF-2014M3C7A1046042), a grant from the National University Hospital of the Ministry of Health & Welfare, Republic of Korea (H18C0630 & H19C0149), a grant from the National University Hospital of the Ministry of Science and ICT, Republic of Korea (H19C0231), a grant from the National University of Aging, United States of America (1U1AAG072177), a grant from the National University of Aging, United States of America (1U1AAG072177), a grant from the National University of Aging, United States of America (1U1AAG072177), a grant from the National University of Aging, United States of America (1U1AAG072177). The funding source had no role in the study design, data collection, data analysis, or decision to submit for publication.

Data Availability

The data of the current study are not freely accessible by the IRB. Requests for data access can be submitted to the administrative coordinator of the KBASE Research Group (E-mail: kbasecohort@gmail.com). The data are available from the independent data-sharing committee of the KBASE Research Group. The data are available from the independent data-sharing committee of the KBASE Research Group on reasonable request after approval by the IRB. The data can be requested from the independent data-sharing committee of the KBASE Research Group.

Conflict of Interest

The authors have no conflict of interest to report.

Supplementary Material

The supplementary material is available in the online version of this article: https://dx.doi.org/10.3233/JAD-220911.
REFERENCES


